Abrilada — CareFirst (Caremark)

Initial criteria

• Member has moderate or severe immunotherapy-related inflammatory arthritis AND has had an inadequate response to corticosteroids or a conventional synthetic drug (e.g., methotrexate, sulfasalazine, leflunomide, hydroxychloroquine) OR has intolerance or contraindication to corticosteroids and a conventional synthetic drug

Approval duration

12 months